Aclaris Therapeutics (ACRS) Equity Ratio: 2017-2025
Historic Equity Ratio for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to 0.68.
- Aclaris Therapeutics' Equity Ratio fell 4.12% to 0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.68, marking a year-over-year decrease of 4.12%. This contributed to the annual value of 0.71 for FY2024, which is 11.33% down from last year.
- Aclaris Therapeutics' Equity Ratio amounted to 0.68 in Q3 2025, which was down 1.76% from 0.70 recorded in Q2 2025.
- Over the past 5 years, Aclaris Therapeutics' Equity Ratio peaked at 0.85 during Q2 2022, and registered a low of 0.68 during Q3 2025.
- For the 3-year period, Aclaris Therapeutics' Equity Ratio averaged around 0.75, with its median value being 0.73 (2025).
- Per our database at Business Quant, Aclaris Therapeutics' Equity Ratio surged by 47.69% in 2021 and then fell by 16.17% in 2025.
- Over the past 5 years, Aclaris Therapeutics' Equity Ratio (Quarterly) stood at 0.79 in 2021, then declined by 1.19% to 0.78 in 2022, then rose by 2.58% to 0.80 in 2023, then decreased by 11.33% to 0.71 in 2024, then dropped by 4.12% to 0.68 in 2025.
- Its last three reported values are 0.68 in Q3 2025, 0.70 for Q2 2025, and 0.73 during Q1 2025.